On the stock market since 2012, it operates in the world of health and science. It has 452 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 23% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $3.0B would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 29% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 66% a year on average.
There is $3.0B in the vault; even if every debt were paid off, $3.0B would remain.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, GLPG sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: GLPG is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.